Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells

References

• Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10:183–203. doi:10.1080/19420862.2018.1415671.
   PubMed Web of Science ®Google Scholar
• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14. doi:10.4161/19420862.2015.989042.
   PubMed Web of Science ®Google Scholar
• Nunez-Prado N, Compte M, Harwood S, Alvarez-Mendez A, Lykkemark S, Sanz L, Álvarez-Vallina L. The coming of age of engineered multivalent antibodies. Drug Discov Today. 2015;20:588–594. doi:10.1016/j.drudis.2015.02.013.
   PubMed Web of Science ®Google Scholar
• Holliger P, Winter G. Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother. 1997;45:128–130. doi:10.1007/s002620050414.
   PubMed Web of Science ®Google Scholar
• Stork R, Campigna E, Robert B, Muller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. 2009;284:25612–25619. doi:10.1074/jbc.M109.027078.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–977. doi:10.1126/science.1158545.
   PubMed Web of Science ®Google Scholar
• Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004;279:53907–53914. doi:10.1074/jbc.M407888200.
   PubMed Web of Science ®Google Scholar
• Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. 2001;276:7346–7350. doi:10.1074/jbc.M007734200.
   PubMed Web of Science ®Google Scholar
• Raso V, Griffin T. Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res. 1981;41:2073–2078.
   PubMed Web of Science ®Google Scholar
• Suresh MR, Cuello AC, Milstein C. Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol. 1986;121:210–228.
   PubMed Web of Science ®Google Scholar
• Kriangkum J, Xu B, Nagata LP, Fulton RE, Suresh MR. Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng. 2001;18:31–40. doi:10.1016/S1389-0344(01)00083-1.
   PubMedGoogle Scholar
• Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65:1471–1478. doi:10.1158/0008-5472.CAN-04-4557.
   PubMed Web of Science ®Google Scholar
• Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003;44:1962–1969.
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 1993;90:6444–6448. doi:10.1073/pnas.90.14.6444.
   PubMed Web of Science ®Google Scholar
• Liu MY, Hu XP, Xie M, Jiang SJ, Li LJ, Liu DX, Yang XS. Secretory expression of a bispecific antibody targeting tumor necrosis factor and ED-B fibronectin in Pichia pastoris and its functional analysis. Biotechnol Lett. 2014;36:2425–2431. doi:10.1007/s10529-014-1630-2.
   PubMed Web of Science ®Google Scholar
• Takagi H, Kadowaki K, Udaka S. Screening and characterization of protein-hyperproducing bacteria without detectable exoprotease activity. Agric Biol Chem. 1989;53:691–699.
   Web of Science ®Google Scholar
• Ilk N, Schumi CT, Bohle B, Egelseer EM, Sleytr UB. Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy. Microb Cell Fact. 2011;10. doi:10.1186/1475-2859-10-6.
   PubMed Web of Science ®Google Scholar
• Zou C, Duan XG, Wu J. Efficient extracellular expression of Bacillus deramificans pullulanase in Brevibacillus choshinensis. J Ind Microbiol Biotechnol. 2016;43:495–504. doi:10.1007/s10295-016-1735-9.
   PubMed Web of Science ®Google Scholar
• Miyauchi A, Ozawa M, Mizukami M, Yashiro K, Ebisu S, Tojo T, Fujii T, Takagi H. Structural conversion from non-native to native form of recombinant human epidermal growth factor by Brevibacillus choshinensis. Biosci Biotechnol Biochem. 1999;63:1965–1969. doi:10.1271/bbb.63.1965.
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Witte L, Zhu Z. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun. 2004;318:507–513. doi:10.1016/j.bbrc.2004.04.135.
   PubMed Web of Science ®Google Scholar
• Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43:1129–1143. doi:10.1016/j.molimm.2005.07.034.
   PubMed Web of Science ®Google Scholar
• Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res. 2006;12:4036–4042. doi:10.1158/1078-0432.CCR-06-0059.
   PubMed Web of Science ®Google Scholar
• Asano R, Kumagai T, Nagai K, Taki S, Shimomura I, Arai K, Ogata H, Okada M, Hayasaka F, Sanada H, et al. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Eng Des Sel. 2013;26:359–367. doi:10.1093/protein/gzt009.
   PubMed Web of Science ®Google Scholar
• Sugiyama A, Umetsu M, Nakazawa H, Niide T, Onodera T, Hosokawa K, Hattori S, Asano R, Kumagai I. A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity. Sci Rep-Uk. 2017;7:2862. doi:10.1038/s41598-017-03101-4.
   Web of Science ®Google Scholar
• Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel. 2004;17:357–366. doi:10.1093/protein/gzh091.
   PubMed Web of Science ®Google Scholar
• Asano R, Ikoma K, Sone Y, Kawaguchi H, Taki S, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, et al. Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem. 2010;285:20844–20849. doi:10.1074/jbc.M110.120444.
   PubMed Web of Science ®Google Scholar
• Asano R, Ikoma K, Shimomura I, Taki S, Nakanishi T, Umetsu M, Kumagai I. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody. J Biol Chem. 2011;286:1812–1818. doi:10.1074/jbc.M110.172957.
   PubMed Web of Science ®Google Scholar
• Frenzel A, Hust M, Schirrmann T. Expression of recombinant antibodies. Front Immunol. 2013;4. doi:10.3389/fimmu.2013.00217.
   PubMed Web of Science ®Google Scholar
• Kufer P, Lutterbuse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol. 2004;22:238–244. doi:10.1016/j.tibtech.2004.03.006.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin. 2005;26:1–9. doi:10.1111/j.1745-7254.2005.00008.x.
   PubMed Web of Science ®Google Scholar
• Asano R, Nagai K, Makabe K, Takahashi K, Kumagai T, Kawaguchi H, Ogata H, Arai K, Umetsu M, Kumagai I. Structural considerations for functional anti-EGFR x anti-CD3 bispecific diabodies in light of domain order and binding affinity. Oncotarget. 2018;9:13884–13893. doi:10.18632/oncotarget.24490.
   PubMedGoogle Scholar
• Mizukami M, Tokunaga H, Onishi H, Ueno Y, Hanagata H, Miyazaki N, Kiyose N, Ito Y, Ishibashi M, Hagihara Y, et al. Highly efficient production of VHH antibody fragments in Brevibacillus choshinensis expression system. Protein Expr Purif. 2015;105:23–32. doi:10.1016/j.pep.2014.10.001.
   PubMed Web of Science ®Google Scholar
• Mizukami M, Hanagata H, Miyauchi A. Brevibacillus expression system: host-vector system for efficient production of secretory proteins. Curr Pharm Biotechnol. 2010;11:251–258. doi:10.2174/138920110791112031.
   PubMed Web of Science ®Google Scholar
• Ebisu S, Takagi H, Kadowaki K, Yamagata H, Udaka S. The efficient production of human epidermal growth factor by Bacillus brevis. Ann Ny Acad Sci. 1996;782:115–122. doi:10.1111/j.1749-6632.1996.tb40553.x.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Maru T, Tahara K, Sanada H, Umetsu M, Asano R, Kumagai I. Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy. Protein Eng Des Sel. 2013;26:113–122. doi:10.1093/protein/gzs088.
   PubMed Web of Science ®Google Scholar
• Makabe K, Asano R, Ito T, Tsumoto K, Kudo T, Kumagai I. Tumor-directed lymphocyte-activating cytokines: refolding-based preparation of recombinant human interleukin-12 and an antibody variable domain-fused protein by additive-introduced stepwise dialysis. Biochem Biophys Res Commun. 2005;328:98–105. doi:10.1016/j.bbrc.2004.12.193.
   PubMed Web of Science ®Google Scholar
• Shi XZ, Karkut T, Chamankhah M, Alting-Mees M, Hemmingsen SM, Hegedus D. Optimal conditions for the expression of a single-chain antibody (scFv) gene in Pichia pastoris. Protein Expr Purif. 2003;28:321–330. doi:10.1016/S1046-5928(02)00706-4.
   PubMed Web of Science ®Google Scholar
• Studier FW. Protein production by auto-induction in high-density shaking cultures. Protein Expr Purif. 2005;41:207–234. doi:10.1016/j.pep.2005.01.016.
   PubMed Web of Science ®Google Scholar
• Takagi H, Kagiyama S, Kadowaki K, Tsukagoshi N, Udaka S. Genetic-transformation of bacillus-brevis with plasmid DNA by electroporation. Agric Biol Chem. 1989;53:3099–3100.
   Web of Science ®Google Scholar
• Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995;177:61–71.
   PubMed Web of Science ®Google Scholar
• Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem. 2007;282:27659–27665. doi:10.1074/jbc.M704719200.
   PubMed Web of Science ®Google Scholar